A new study published in *Nature* reveals that chemotherapy, especially platinum-based drugs, significantly alters the mutation profiles of childhood cancers at relapse. Researchers found a tripling of private signatures and doubling of the overall mutation burden following treatment, indicating therapy-induced tumor evolution.
The research, published online on July 22, 2026 (doi:10.1038/s41586-026-10803-1), highlights how cancer cells evolve during treatment. The study demonstrates that chemotherapy, particularly platinum-based drugs, is associated with substantial and rapidly detectable mutagenesis in childhood cancers.
The findings suggest that the therapy itself drives changes within the tumor's genetic makeup. Specifically, researchers observed a tripling of what they term “private signatures” – unique mutations specific to individual tumors – and a doubling of the total mutation burden after chemotherapy administration. This indicates that treatment isn’t simply killing cancer cells but also actively shaping their evolutionary trajectory.
The implications of this research are significant for future cancer treatment strategies. Understanding how therapy induces tumor evolution opens opportunities for developing safer, more effective, and potentially “de-escalated” treatments – meaning therapies could be adjusted to minimize the selective pressure that drives these mutations.
We don't rate truth. We strip the spin and show you which perspectives covered the story. You decide.
Read the original coverage
💬 Comments
📜 Comment Policy